TY - JOUR AU - Weinreb, R. N. AU - Aung, T. AU - Medeiros, F. A. PY - 2014 DA - 2014// TI - The pathophysiology and treatment of glaucoma: a review JO - JAMA VL - 311 UR - https://doi.org/10.1001/jama.2014.3192 DO - 10.1001/jama.2014.3192 ID - Weinreb2014 ER - TY - JOUR AU - Tham, Y. C. AU - Li, X. AU - Wong, T. Y. AU - Quigley, H. A. AU - Aung, T. AU - Cheng, C. Y. PY - 2014 DA - 2014// TI - Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis JO - Ophthalmology VL - 121 UR - https://doi.org/10.1016/j.ophtha.2014.05.013 DO - 10.1016/j.ophtha.2014.05.013 ID - Tham2014 ER - TY - JOUR AU - Yamamoto, T. AU - Iwase, A. AU - Araie, M. AU - Suzuki, Y. AU - Abe, H. AU - Shirato, S. AU - Kuwayama, Y. AU - Mishima, H. K. AU - Shimizu, H. AU - Tomita, G. PY - 2005 DA - 2005// TI - The Tajimi study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population JO - Ophthalmology VL - 112 UR - https://doi.org/10.1016/j.ophtha.2005.05.012 DO - 10.1016/j.ophtha.2005.05.012 ID - Yamamoto2005 ER - TY - JOUR PY - 2018 DA - 2018// TI - The Japan guidelines for Glaucoma (fourth edition) JO - Nippon Ganka Gakkai Zasshi VL - 122 ID - ref4 ER - TY - JOUR AU - Prum, B. E. AU - Rosenberg, L. F. AU - Gedde, S. J. AU - Mansberger, S. L. AU - Stein, J. D. AU - Moroi, S. E. AU - Herndon, L. W. AU - Lim, M. C. AU - Williams, R. D. PY - 2016 DA - 2016// TI - Primary open-angle Glaucoma preferred practice patternĀ® guidelines JO - Ophthalmology VL - 123 UR - https://doi.org/10.1016/j.ophtha.2015.10.053 DO - 10.1016/j.ophtha.2015.10.053 ID - Prum2016 ER - TY - STD TI - National Institute for Health and Care Excellence. Glaucoma: diagnosis and management. NICE Guideline; 2017. Available at: https://www.nice.org.uk/guidance/ng81. Accessed 13 June 2019. UR - https://www.nice.org.uk/guidance/ng81 ID - ref6 ER - TY - JOUR AU - Honjo, M. AU - Tanihara, H. PY - 2018 DA - 2018// TI - Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma JO - Jpn J Ophthalmol VL - 62 UR - https://doi.org/10.1007/s10384-018-0566-9 DO - 10.1007/s10384-018-0566-9 ID - Honjo2018 ER - TY - JOUR AU - Honjo, M. AU - Tanihara, H. AU - Inatani, M. AU - Kido, N. AU - Sawamura, T. AU - Yue, B. Y. AU - Narumiya, S. AU - Honda, Y. PY - 2001 DA - 2001// TI - Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility JO - Invest Ophthalmol Vis Sci VL - 42 ID - Honjo2001 ER - TY - JOUR AU - Rao, P. V. AU - Deng, P. -. F. AU - Kumar, J. AU - Epstein, D. L. PY - 2001 DA - 2001// TI - Modulation of aqueous humor outflow facility by the rho kinaseā€“specific inhibitor Y-27632 JO - Invest Ophthalmol Vis Sci VL - 42 ID - Rao2001 ER - TY - JOUR AU - Tanihara, H. AU - Inatani, M. AU - Honjo, M. AU - Tokushige, H. AU - Azuma, J. AU - Araie, M. PY - 2008 DA - 2008// TI - Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers JO - Arch Ophthalmol VL - 126 UR - https://doi.org/10.1001/archophthalmol.2007.76 DO - 10.1001/archophthalmol.2007.76 ID - Tanihara2008 ER - TY - JOUR AU - Garnock-Jones, K. P. PY - 2014 DA - 2014// TI - Ripasudil: first global approval JO - Drugs VL - 74 UR - https://doi.org/10.1007/s40265-014-0333-2 DO - 10.1007/s40265-014-0333-2 ID - Garnock-Jones2014 ER - TY - JOUR AU - Inoue, T. AU - Tanihara, H. PY - 2017 DA - 2017// TI - Ripasudil hydrochloride hydrate: targeting rho kinase in the treatment of glaucoma JO - Expert Opin Pharmacother VL - 18 UR - https://doi.org/10.1080/14656566.2017.1378344 DO - 10.1080/14656566.2017.1378344 ID - Inoue2017 ER - TY - JOUR AU - Tanihara, H. AU - Inoue, T. AU - Yamamoto, T. AU - Kuwayama, Y. AU - Abe, H. AU - Araie, M. PY - 2013 DA - 2013// TI - Phase 1 clinical trials of a selective rho kinase inhibitor, K-115 JO - JAMA Ophthalmol VL - 131 UR - https://doi.org/10.1001/jamaophthalmol.2013.323 DO - 10.1001/jamaophthalmol.2013.323 ID - Tanihara2013 ER - TY - JOUR AU - Tanihara, H. AU - Inoue, T. AU - Yamamoto, T. AU - Kuwayama, Y. AU - Abe, H. AU - Araie, M. PY - 2013 DA - 2013// TI - Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension JO - Am J Ophthalmol VL - 156 UR - https://doi.org/10.1016/j.ajo.2013.05.016 DO - 10.1016/j.ajo.2013.05.016 ID - Tanihara2013 ER - TY - JOUR AU - Tanihara, H. AU - Inoue, T. AU - Yamamoto, T. AU - Kuwayama, Y. AU - Abe, H. AU - Fukushima, A. AU - Suganami, H. AU - Araie, M. PY - 2016 DA - 2016// TI - K-115 clinical study group, Uchino M: one-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension JO - Acta Ophthalmol VL - 94 UR - https://doi.org/10.1111/aos.12829 DO - 10.1111/aos.12829 ID - Tanihara2016 ER - TY - JOUR AU - Tanihara, H. AU - Inoue, T. AU - Yamamoto, T. AU - Kuwayama, Y. AU - Abe, H. AU - Suganami, H. AU - Araie, M. PY - 2015 DA - 2015// TI - Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials JO - JAMA Ophthalmol VL - 133 UR - https://doi.org/10.1001/jamaophthalmol.2015.0525 DO - 10.1001/jamaophthalmol.2015.0525 ID - Tanihara2015 ER - TY - JOUR AU - Tanihara, H. AU - Inoue, T. AU - Yamamoto, T. AU - Kuwayama, Y. AU - Abe, H. AU - Suganami, H. AU - Araie, M. PY - 2015 DA - 2015// TI - K-115 clinical study group: intra-ocular pressure-lowering effects of a rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study JO - Acta Ophthalmol VL - 93 UR - https://doi.org/10.1111/aos.12599 DO - 10.1111/aos.12599 ID - Tanihara2015 ER - TY - JOUR AU - Tanihara, H. AU - Kakuda, T. AU - Sano, T. AU - Kanno, T. AU - Imada, R. AU - Shingaki, W. AU - Gunji, R. PY - 2019 DA - 2019// TI - Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 3-month interim analysis of ROCK-J, a post-marketing surveillance study JO - Adv Ther VL - 36 UR - https://doi.org/10.1007/s12325-018-0863-1 DO - 10.1007/s12325-018-0863-1 ID - Tanihara2019 ER - TY - JOUR AU - Kashiwagi, K. AU - Furuya, T. PY - 2014 DA - 2014// TI - Persistence with topical glaucoma therapy among newly diagnosed Japanese patients JO - Jpn J Ophthalmol VL - 58 UR - https://doi.org/10.1007/s10384-013-0284-2 DO - 10.1007/s10384-013-0284-2 ID - Kashiwagi2014 ER - TY - JOUR AU - Newman-Casey, P. A. AU - Robin, A. L. AU - Blachley, T. AU - Farris, K. AU - Heisler, M. AU - Resnicow, K. AU - Lee, P. P. PY - 2015 DA - 2015// TI - The most common barriers to glaucoma medication adherence: a cross-sectional survey JO - Ophthalmology VL - 122 UR - https://doi.org/10.1016/j.ophtha.2015.03.026 DO - 10.1016/j.ophtha.2015.03.026 ID - Newman-Casey2015 ER - TY - JOUR AU - Chrysant, S. G. PY - 2008 DA - 2008// TI - Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema JO - J Clin Hypertens (Greenwich) VL - 10 UR - https://doi.org/10.1111/j.1751-7176.2008.00006.x DO - 10.1111/j.1751-7176.2008.00006.x ID - Chrysant2008 ER - TY - JOUR AU - Jarernsiripornkul, N. AU - Krska, J. AU - Capps, P. A. AU - Richards, R. M. AU - Lee, A. PY - 2002 DA - 2002// TI - Patient reporting of potential adverse drug reactions: a methodological study JO - Br J Clin Pharmacol VL - 53 UR - https://doi.org/10.1046/j.0306-5251.2001.01547.x DO - 10.1046/j.0306-5251.2001.01547.x ID - Jarernsiripornkul2002 ER - TY - JOUR AU - Sakamoto, E. AU - Ishida, W. AU - Sumi, T. AU - Kishimoto, T. AU - Tada, K. AU - Fukuda, K. AU - Yoneda, T. AU - Kuroiwa, H. AU - Terao, E. AU - Fujisawa, Y. PY - 2019 DA - 2019// TI - Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% ripasudil ophthalmic solution clinical trial JO - Sci Rep VL - 9 UR - https://doi.org/10.1038/s41598-019-40255-9 DO - 10.1038/s41598-019-40255-9 ID - Sakamoto2019 ER - TY - JOUR AU - Serle, J. B. AU - Katz, L. J. AU - McLaurin, E. AU - Heah, T. AU - Ramirez-Davis, N. AU - Usner, D. W. AU - Novack, G. D. AU - Kopczynski, C. C. PY - 2018 DA - 2018// TI - Rocket, groups R-S: two phase 3 clinical trials comparing the safety and efficacy of Netarsudil to Timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2) JO - Am J Ophthalmol VL - 186 UR - https://doi.org/10.1016/j.ajo.2017.11.019 DO - 10.1016/j.ajo.2017.11.019 ID - Serle2018 ER - TY - JOUR AU - Kahook, M. Y. AU - Serle, J. B. AU - Mah, F. S. AU - Kim, T. AU - Raizman, M. B. AU - Heah, T. AU - Ramirez-Davis, N. AU - Kopczynski, C. C. AU - Usner, D. W. AU - Novack, G. D. PY - 2019 DA - 2019// TI - Long-term safety and ocular hypotensive efficacy evaluation of Netarsudil ophthalmic solution: rho kinase elevated IOP treatment trial (ROCKET-2) JO - Am J Ophthalmol VL - 200 UR - https://doi.org/10.1016/j.ajo.2019.01.003 DO - 10.1016/j.ajo.2019.01.003 ID - Kahook2019 ER - TY - JOUR AU - Okumura, N. AU - Okazaki, Y. AU - Inoue, R. AU - Kakutani, K. AU - Nakano, S. AU - Kinoshita, S. AU - Koizumi, N. PY - 2016 DA - 2016// TI - Effect of the rho-associated kinase inhibitor eye drop (Ripasudil) on corneal endothelial wound healing JO - Invest Ophthalmol Vis Sci VL - 57 UR - https://doi.org/10.1167/iovs.15-18586 DO - 10.1167/iovs.15-18586 ID - Okumura2016 ER - TY - JOUR AU - Havens, S. J. AU - Gulati, V. PY - 2016 DA - 2016// TI - Neovascular glaucoma JO - Dev Ophthalmol VL - 55 UR - https://doi.org/10.1159/000431196 DO - 10.1159/000431196 ID - Havens2016 ER -